Long-term IGF-I treatment of children with Laron syndrome increases adiposity
- PMID: 16442822
- DOI: 10.1016/j.ghir.2005.12.001
Long-term IGF-I treatment of children with Laron syndrome increases adiposity
Abstract
Laron syndrome (LS) is an autosomal recessive disease caused by deletions or mutations in the GH receptor gene leading to an inability of insulin-like growth factor I (IGF-I) generation. Among the major resulting body changes are dwarfism and obesity. The only effective treatment is daily administration of biosynthetic IGF-I. Body composition determination by DEXA (dual energy X-ray absorptiometry) of three girls with LS treated by IGF-I for 1, 3 and 11 1/2 years, respectively, revealed that concomitantly with the increase in growth there was a significant increase in body adipose tissue to double or triple the normal values. Due to the underdevelopment of the muscular and skeletal systems body mass index (BMI) did not accurately reflect the degree of obesity. In conclusion, IGF-I similar to insulin, exerts an adipogenic effect.
Similar articles
-
Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity).Pediatr Endocrinol Rev. 2008 Mar;5(3):766-71. Pediatr Endocrinol Rev. 2008. PMID: 18367997 Review.
-
Body composition in untreated adult patients with Laron syndrome (primary GH insensitivity).Clin Endocrinol (Oxf). 2006 Jul;65(1):114-7. doi: 10.1111/j.1365-2265.2006.02558.x. Clin Endocrinol (Oxf). 2006. PMID: 16817829
-
IGF-I replacement therapy in children with congenital IGF-I deficiency (Laron syndrome) maintains heart dimension and function.Growth Horm IGF Res. 2009 Jun;19(3):280-2. doi: 10.1016/j.ghir.2008.11.004. Epub 2008 Dec 30. Growth Horm IGF Res. 2009. PMID: 19117781
-
Biphasic response of subscapular skinfold thickness to hGH or IGF-1 administration to patients with congenital IGHD, congenital MPHD and Laron syndrome.Obes Res Clin Pract. 2014 Jan-Feb;8(1):e55-62. doi: 10.1016/j.orcp.2012.11.001. Obes Res Clin Pract. 2014. PMID: 24548577
-
Statement 5: the first line of treatment for children with idiopathic short stature (ISS) and low serum insulin-like growth factor-I (IGF-I) should be IGF-I.Pediatr Endocrinol Rev. 2008 Apr;5 Suppl 3:853-6. Pediatr Endocrinol Rev. 2008. PMID: 18438329 Review. No abstract available.
Cited by
-
POTENTIAL NON-GROWTH USES OF rhIGF-I.Growth Genet Horm. 2007 Mar;23(1):1-7. Growth Genet Horm. 2007. PMID: 19081780 Free PMC article. No abstract available.
-
Treatment of dwarfism with recombinant human insulin-like growth factor-1.Dtsch Arztebl Int. 2009 Oct;106(43):703-9. doi: 10.3238/arztebl.2009.0703. Epub 2009 Oct 23. Dtsch Arztebl Int. 2009. PMID: 19946434 Free PMC article. Review.
-
Human conditions of insulin-like growth factor-I (IGF-I) deficiency.J Transl Med. 2012 Nov 14;10:224. doi: 10.1186/1479-5876-10-224. J Transl Med. 2012. PMID: 23148873 Free PMC article. Review.
-
Relative growth hormone deficiency and cortisol excess are associated with increased cardiovascular risk markers in obese adolescent girls.J Clin Endocrinol Metab. 2009 Aug;94(8):2864-71. doi: 10.1210/jc.2009-0380. Epub 2009 May 12. J Clin Endocrinol Metab. 2009. PMID: 19435823 Free PMC article.
-
The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency.Endocr Connect. 2017 Nov;6(8):R171-R181. doi: 10.1530/EC-17-0203. Epub 2017 Sep 25. Endocr Connect. 2017. PMID: 28947559 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources